Stromal-derived factor 1 (SDF-1) is a -CXC- chemokine that plays a critical role in embryonic and adult hematopoiesis, and its specific receptor, CXCR4, has been implicated in stem cell homing. In this study, it is shown that the addition of SDF-1 to long-term cultures (LTCs) of normal human marrow can selectively, reversibly, and specifically block the S-phase entry of primitive quiescent erythroid and granulopoietic colony-forming cells (CFCs) present in the adherent layer. Conversely, addition of anti–SDF-1 antibody or SDF-1(G2), a specific CXCR4 antagonist, to preactivated human LTCs prevented both types of primitive CFCs from re-entering a quiescent state, demonstrating that endogenous SDF-1 contributes to the control of primitive CFC proliferation in the LTC system. Interestingly, SDF-1 failed to arrest the proliferation of primitive chronic myeloid leukemia CFCs in the adherent layer of LTCs containing normal marrow stromal cells. In vivo, injection of SDF-1 arrested the cycling of normal human LTC-initiating cells as well as primitive CFCs in the marrow of nonobese diabetic/severe combined immunodeficient mice engrafted with human cord blood cells. Conversely, injection of the antagonist, SDF-1(G2), reactivated the cycling of quiescent primitive human CFCs present in the marrow of mice engrafted with human marrow cells. These studies are the first to demonstrate a potential physiological role of SDF-1 in regulating the cell-cycle status of primitive hematopoietic cells and suggest that the deregulated cycling activity of primitive chronic myeloid leukemia (CML) cells is due to the BCR-ABL–mediated disruption of a pathway shared by multiple chemokine receptors.

The exogenous control of blood cell output in vivo is a highly complex process involving multiple positive and negative regulators. Many of these are cytokines with activities that are specific to particular lineages and stages of differentiation in the hematopoietic cell hierarchy. Together, the intracellular signaling mechanisms activated by these cytokines determine the proportion of cells in each compartment that remain viable, that proliferate, and that initiate and complete the various programs of hematopoietic differentiation. In the healthy adult, a majority of the most primitive hematopoietic cells are, at any given moment, quiescent.1-7 However, over time, all slowly and randomly enter the cell cycle and proliferate.3,8,9 In successively later compartments, the proportion of dividing cells increases progressively, as shown by studies of distinct subpopulations of in vitro and in vivo colony-forming cells (CFCs) and their precursors detected as long-term culture–initiating cells (LTC-ICs). The LTC system has been particularly useful for allowing the identification of particular cytokines that can either stimulate or inhibit the cell-cycle progression of primitive hematopoietic cells in a stage-specific fashion. In such cultures, the high proliferative potential (HPP)–CFCs in the adherent layer are maintained in a quiescent state unless the cultures are appropriately stimulated. In contrast, the low proliferative potential (LPP)–CFCs cycle continuously, thus mimicking the situation in normal adult marrow. Thus, each week when fresh medium containing horse serum is added to such LTCs, the prevailing endogenous negative signals active on these HPP-CFCs in the adherent layer are overcome; this results in a transient but pronounced activation of these cells into cycle that peaks 2 to 3 days later.10,11 In previous studies, we have identified a variety of cytokines whose addition to LTCs can have an effect similar to that of adding fresh horse serum, either because these cytokines can stimulate HPP-CFC proliferation directly or because they induce the secondary production of such factors.11-14Coincident addition of cytokines that block HPP-CFC activation in this system has similarly allowed various specific inhibitors of HPP-CFC mitogenesis to be identified. These include transforming growth factor β (TGF-β)11 and 2 members of the chemokine family: monocyte chemoattractant protein-1 (MCP-1)15 and macrophage inhibitory protein 1α (MIP-1α).16Furthermore, the addition of specific antibodies or antagonists of these inhibitors to LTCs 2 to 3 days after a half-medium change (when the activating stimuli begin to decline and inhibitors produced within the cultures begin to regain dominance) has shown that both TGF-β and MCP-1 (but not MIP-1α) are endogenously active in this system and that both are required to arrest the cycling of the primitive progenitors in the adherent layer. Thus, when either of these endogenous inhibitors is inactivated, the HPP-CFCs in the adherent layer fail to return to a quiescent state another 4 to 5 days later.11,15 Interestingly, the autonomously proliferating neoplastic (Ph+) HPP-CFCs produced from primitive chronic myeloid leukemia (CML) progenitors17 are insensitive to the cytostatic activity of either MIP-1α or MCP-1 in the LTC system,15,16 in spite of a normal responsiveness to TGF-β.18 

More recently, we have examined the proliferative activity of primitive normal human progenitors in engrafted NOD/LtSz-scid/scid (NOD/SCID) mice and have used this model to test the ability of various cytokines to stimulate or inhibit the turnover of different normal human progenitor subsets in vivo.19-21 Up to 6 weeks after transplantation, all of the human CFCs and LTC-ICs present in the marrow of NOD/SCID mice that received human adult marrow or cord blood cell transplants proliferate rapidly. This situation persists for many months in the cord blood–engrafted mice. However, after 10 weeks, further proliferation of the human CFCs is markedly downregulated in human marrow–engrafted mice, even though the LTC-ICs continue to divide. These differences in the cycling behavior of human marrow–derived CFCs and LTC-ICs in this xenotransplant model suggest that LTC-ICs and CFCs are sensitive to different proliferation-control mechanisms. Subsequent studies showed this to be the case. Injections of TGF-β, MCP-1, and MIP-1α were all able to arrest the endogenously stimulated cycling of human CFCs and LTC-ICs in NOD/SCID mice that received transplants, but with different target cell specificities and TGF-β was the only cytokine that could inhibit the proliferation of human LTC-ICs.21 

As a follow-up to these studies, we surveyed another 3 chemokines for their ability to selectively inhibit the cell-cycle progression of normal human HPP-CFCs in the LTC system. The 3 chemokines selected were stromal-derived factor 1 (SDF-1), hemofiltrate cc chemokine (HCC-1), and I-309. SDF-1 was chosen in part because its receptor, CXCR4, has been found on most types of primitive human hematopoietic cells.22-24 SDF-1 has also been found to be a potent inducer of primitive human hematopoietic cell migration in vitro and has been implicated in human stem cell homing in vivo.24-28 Evidence that SDF-1 can mobilize murine stem cells in vivo was also recently reported.29 However, the potential of this chemokine to regulate the proliferative status of primitive hematopoietic progenitors has not been previously investigated. HCC-1 was of interest because it is structurally related to MIP-1α and acts via receptors that also recognize MIP-1α.30 I-309 is another recently described chemokine31 whose action on hematopoietic cells has not been previously reported. On the basis of the positive results obtained in our initial studies, a series of additional experiments were then undertaken: (1) to investigate the sensitivity of primitive CML progenitors to SDF-1; (2) to determine whether this chemokine might also be active as an inhibitor in vivo in human cell engrafted–NOD/SCID mice; and (3) to explore its potential endogenous role as an inhibitor with the use of a specific anti–SDF-1 antibody and a specific SDF-1 antagonist we have recently developed.32 

Cytokines

Human TGF-β1, HCC-1, I-309, a neutralizing goat anti–SDF-1 antibody (15 to 30 μg/mL able to neutralize 100 ng/mL human SDF-1), and control goat immunoglobulin (Ig)–G were purchased from R&D Systems (Minneapolis, MN). SDF-1 and the antagonist, SDF-1(G2), were synthesized by stepwise solid-phase methods and purified as previously described.33 Purity of the products was assessed by ion-exchange high-pressure liquid chromatography and mass spectrometry. SDF-1(G2) is a variant of SDF-1 in which a glycine residue is substituted for the proline normally at position 2. This results in a complete loss of activity although the receptor-binding affinity of SDF-1(G2) is only approximately 3-fold less than that of SDF-1, thus making it an effective antagonist.32 

Human cells

Cord blood was obtained with informed consent from the mothers of healthy, full-term infants. Normal adult human bone marrow cells were obtained as cadaveric marrow samples from the Northwest Tissue Center (Seattle, WA) or as leftover aspirate material from consenting donors of allogeneic marrow transplants harvested at our center. Peripheral blood cells were obtained from 7 patients with Ph+/BCR-ABL+ CML in chronic phase but with high white blood cell (WBC) counts (> 50 × 109/L [50 000/μL]) as discard material from samples taken for diagnostic or follow-up purposes. For experiments with normal cord blood or adult marrow, low-density (< 1.077 g/mL) cells were used either as fresh or as previously cryopreserved material. Low-density CML cells were further depleted of lineage-marker–positive cells34 and were stored frozen until required.

In vitro cytokine experiments

Four to 8 × 106 washed normal human marrow or CML blood cells were suspended in 2.5 mL myeloid LTC medium (MyeloCult; StemCell Technologies, Vancouver, BC, Canada) supplemented with 10−6 M freshly dissolved hydrocortisone (Sigma Chemicals, St Louis, MO); the cells were then placed into 35-mm tissue-culture dishes containing pre-established, irradiated adherent cell layers of normal human marrow as previously described.16 After an initial 7- to 10-day period of incubation at 33°C, half of the medium was replaced with fresh complete LTC medium and other agents, either simultaneously (cytokines) or 2 to 3 days later (antibodies or the SDF-1 antagonist). At the appropriate time, the nonadherent cells were removed and the adherent cells harvested enzymatically for assessment of the numbers and cycling activity of the CFCs present as described below.10 

Enzyme-linked immunosorbent assay measurements of SDF-1 concentrations in LTC supernatants

Cells were removed from media harvested from LTCs that were being analyzed for progenitor cycling status, and the supernatants were stored frozen. SDF-1 concentrations were simultaneously determined on the thawed supernatants by means of a commercial enzyme-linked immunosorbent assay (ELISA) kit (Quantikine; R&D Systems) according to the manufacturer's directions.

Animals

NOD/SCID mice were bred and maintained in the animal facility of the British Columbia Cancer Research Centre (Vancouver, BC, Canada) from mice originally obtained from the Jackson Laboratories (Bar Harbor, ME). All animals were kept in microisolator units and provided with sterilized food and water. Mice were irradiated (350 cGy of137Cs γ-rays) at 6 to 8 weeks of age and then injected intravenously with human cells suspended in phosphate-buffered saline (PBS) (107 or 2 × 107 low-density, trypan blue–excluding cord blood or adult marrow cells per recipient mouse, respectively). Thereafter, the drinking water was acidified (pH = 3) and supplemented with 100 mg/L ciprofloxacin (Bayer, Leverkusen, Germany). At 6 to 8 weeks after transplantation, cord blood–engrafted mice were given 2 intraperitoneal injections, 24 hours apart, of 10 μg SDF-1 diluted in PBS (or an equal volume of PBS as a control). Similarly, bone marrow–engrafted mice were each injected twice with 10 μg SDF-1(G2), but not until 10 to 12 weeks after transplantation. At 1 day after the second injection, the mice were killed, and the marrow cells then removed from the 4 hind leg bones. Cell counts, phenotyping, and 3H-thymidine suicide assays were performed individually on the cells obtained from each mouse.

Flow cytometry

Cells removed from the mice were counted, subjected to red cell lysis by treatment with 8.3% ammonium chloride, and then washed in Hanks balanced salt solution (StemCell Technologies) with 2% fetal calf serum (HF/2). Nonspecific antibody binding was inhibited by first incubating the cells with human serum and 3 μg/mL anti–mouse IgG receptor antibody 2.4G2 for 10 minutes at 0°C to block Fc receptors.35 The cells were then incubated for 30 minutes at 0°C with the following directly labeled antibodies: anti-CD34–fluorescein isothiocyanate (FITC) (8G12),36anti–human CD19–phycoerythrin (PE), and anti–human CD20-PE (Becton Dickinson, San Jose, CA), all in one tube to permit the identification of human CD34CD19+ and/or CD20+ B-lineage cells (referred to as CD34CD19/20+ cells); and, in another tube, anti-CD34–PE, anti-CD45–FITC (Hlel) (Becton Dickinson), and anti-CD71–FITC (OKT-9) to allow the total human cell population (referred to as CD45/71+ cells) to be quantified and, at the same time, to permit isolation by fluorescence-activated cell sorting (FACS) of the human CD34+ subset for subsequent assessment of CFCs and LTC-ICs. Cells were then washed twice in HF/2 with 2 μg/mL propidium iodide (PI) (Sigma Chemicals) added to the second wash. Cells were sorted on a FACStar+ (Becton Dickinson) equipped with 5-W argon and 30-mW helium neon lasers. Specific fluorescence of FITC and PE was detected by means of gates that excluded more than 99.9% of cells stained with irrelevant isotype control antibodies labeled with the same fluorochromes. Under these conditions, no positive staining of mouse marrow cells (obtained from NOD/SCID mice that were not transplant recipients) was seen. LYSIS II software (Becton Dickinson) was used for acquisition and analysis of FACS data. For each analysis, a minimum of 20 000 viable (PI) cells were assessed, and positive staining was scored only when more than 5 positive events were recorded.

In vitro progenitor assays

Human CD34+ cells isolated from the marrow of engrafted mice were assayed for CFCs at concentrations ranging from 250 to 9000 cells per 1.1 mL in duplicate 1.1 mL standard serum containing methylcellulose cultures (MethoCult 4230; StemCell Technologies) supplemented with 3000 U/L (3 U/mL) human erythropoietin (StemCell Technologies); 50 ng/mL Steel factor (SF) (expressed and purified in our laboratory); and 20 ng/mL each of the following: interleukin (IL)–3; granulocyte-macrophage colony-stimulating factor (both from Novartis, Basel, Switzerland); granuloctye colony-stimulating factor (G-CSF) (StemCell Technologies); and IL-6 (Cangene, Mississauga, ON, Canada). Myeloid CFCs (granulocyte-macrophage colony-forming units [CFU-GMs]) and erythroid CFCs (erythroid burst-forming units [BFU-Es]) were subcategorized as HPP and LPP subsets according to previously described criteria.10 Human CD34+ cells were assayed for LTC-ICs by assessment of the number of CFCs produced after 6 weeks in duplicate 1-mL cultures, each initiated with from 960 to 9000 cells. These were cocultured with irradiated mouse marrow fibroblasts previously engineered to produce SF, G-CSF, and IL-3 and maintained in hydrocortisone-supplemented myeloid LTC medium (MyeloCult), as previously described in detail.37 LTC-IC numbers were calculated on the assumption that, on average, each human cord blood–derived LTC-IC produces 28 CFCs and each human marrow–derived LTC-IC produces 18 CFCs after 6 weeks.37 

3H-thymidine suicide assay

For assessment of the cycling activity of CFCs, sorted CD34+ cells were resuspended in Iscoves medium, and equal aliquots were then incubated at no more than 2 × 106cells per milliliter with and without 20 μCi/mL (.74 MBq/mL) high–specific activity 3H-thymidine (25 Ci/mmol [925 GBq/mmol]) (Amersham, Mississauga, ON, Canada) for 20 minutes at 37°C, as described in detail previously,10 before being washed and assayed for CFCs in duplicate cultures at the same cell concentrations as the untreated cells. The proportion of a given type of CFC in S-phase at the time of harvest was calculated from the loss of colony-forming activity (percentage killed) measured in the assays of the 3H-thymidine–treated cells versus the control cells. The proliferative activity of the LTC-ICs was similarly determined from CFC assays of duplicate 6-week cultures initiated with cells that had been incubated overnight in serum-free medium supplemented with SF, IL-3, and G-CSF, with or without the addition of3H-thymidine, also as described previously.5 

Statistical analyses

Values shown are the mean ± SEM. The Student 2-tailed t test was used to determine significant differences (P < .05).

SDF-1 and HCC-1 block the activation of all primitive CFCs in the adherent cell layer of LTCs initiated with normal adult human marrow

In previous studies, we have shown that the predominantly quiescent HPP-CFCs (both erythroid and granulopoietic) present in the adherent layer of normal human LTCs at least 7 days after a previous half-medium change are stimulated to enter S-phase 2 days following the next addition of fresh medium, and that this response can be blocked by the simultaneous addition of MIP-1α and MCP-1, but not several other chemokines.15,16 In this study, we used the same protocol to investigate whether SDF-1, HCC-1, and I-309 might have similar inhibitory activities. Accordingly, each of these agents was added simultaneously with a half-medium change (resulting in a final concentration of 100 ng/mL in the medium) to LTCs that had been initiated by seeding human marrow cells 7 to 10 days previously onto pre-established irradiated normal human marrow–derived adherent layers. At 2 to 3 days after the addition of new medium (with or without the test agents), when it was anticipated that the HPP-CFCs in the adherent layer of the control cultures would be maximally proliferating, all cultures were harvested and CFC cycling assays performed. As shown in Table 1, the addition of either SDF-1 or HCC-1 prevented the activation (persistance of low percentage killed) of the HPP-CFCs (both the primitive CFU-GMs and the primitive BFU-Es) in the adherent layer of the treated LTCs. I-309 did not have an equivalent effect on the primitive BFU-Es although the decrease in the percentage of the primitive CFU-GMs killed did reach significance (P < .05). In contrast, the proliferative activity of the mature CFU-GMs present in the same chemokine-treated LTC adherent layers and evaluated in the same assays was not affected by any of the treatments. This was shown by the high percentage killed (Table 1). Mature BFU-Es are not found in these cultures in sufficient numbers to allow their cycling status to be reliably assessed.10 Under these conditions, the cytostatic action exerted by SDF-1 and HCC-1 on the HPP-CFCs was completely reversible, as indicated by the finding that the total number of HPP-CFCs (and LPP-CFCs) in the cytokine-treated cultures was the same as in the control cultures (P > .05; data not shown).

Table 1.

Differential effects of selected chemokines on the cycling of various progenitors in the adherent layer of human LTCs

Factor addedKilled by3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 52 ± 4 50 ± 4 49 ± 1 
SDF-1 0 ± 3 0 ± 2 45 ± 3 
HCC-1 8 ± 3 0 ± 2 38 ± 2 
I-309 65 ± 12 28 ± 0 46 ± 1 
Factor addedKilled by3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 52 ± 4 50 ± 4 49 ± 1 
SDF-1 0 ± 3 0 ± 2 45 ± 3 
HCC-1 8 ± 3 0 ± 2 38 ± 2 
I-309 65 ± 12 28 ± 0 46 ± 1 

All chemokines were added simultaneously with a half-medium change to give a final concentration of 100 ng/mL, and their effects assessed 2 to 3 days later. Results shown are the mean ± SEM of data obtained from 2 to 10 independent experiments. A significant effect (P < .0001) on the cycling of the primitive BFU-Es and primitive CFU-GMs was observed when SDF-1 or HCC-1 was added. A slight effect (P < .05) on the cycling of the primitive CFU-GMs (only) was seen when I-309 was added. There was no significant effect of any of the chemokines tested on the cycling of the mature CFU-GMs. The total colony counts in the control groups (no3H-thymidine) ranged from 12 to 385.

SDF-1 is endogenously produced and contributes to the inhibition of HPP-CFC proliferation in the adherent layer of human LTCs

SDF-1 is known to be constitutively produced by many cell types, including endothelial cells and other bone marrow stromal elements38-40 that compose a large fraction of the cells in the adherent layer of LTCs.41,42 Moreover, measurement by ELISA of SDF-1 levels in the medium harvested from variously treated LTCs confirmed that it was present in low but readily detectable concentrations in the supernatants removed 2 to 3 days and 7 days after a first medium change (Table 2). Interestingly, the levels of SDF-1 doubled during this interval, consistent with its continuous endogenous production and replacement of the amounts removed during the previous half-medium change. Surprisingly, the addition of 100 ng/mL exogenous SDF-1 did not alter the levels of SDF-1 detectable in the supernatant of the cultures 2 to 3 days later. However, rapid depletion of exogenously added cytokines from LTC supernatants has been previously documented43 and is presumably due to their variable abilities to be bound to (and possibly degraded by) the cells and extracellular matrix components of the cultures. Thus, the concentrations of cytokines in LTC supernatants can, at best, provide only a relative measure of their effective amounts in the adherent layer, which can be at least 100 × higher.13 43 

Table 2.

SDF-1 levels in the medium of human LTCs given various prior treatments

Prior treatmentTime of assessment (days after medium change)SDF-1 concentration (ng/mL)
Half-medium change 2-3 0.53 ± 0.06  
Half-medium change + SDF-1 2-3 0.35 ± 0.06  
Half-medium change 1.30 ± 0.30  
Half-medium change + SDF-1(G2) (2 to 3 days later) 3.10 ± 1.30 
Prior treatmentTime of assessment (days after medium change)SDF-1 concentration (ng/mL)
Half-medium change 2-3 0.53 ± 0.06  
Half-medium change + SDF-1 2-3 0.35 ± 0.06  
Half-medium change 1.30 ± 0.30  
Half-medium change + SDF-1(G2) (2 to 3 days later) 3.10 ± 1.30 

Values shown are the mean ± SEM from 8 to 10 experiments. SDF-1 was added at 100 ng/mL, and SDF-1 (G2) at 10 μg/mL. The increase in SDF-1 levels over time (from 2 to 3 days to 7 days after a previous half-medium change) is significant (P < .05). The difference between cultures with and without SDF-1 addition is not significant (P > .05). The difference between cultures with and without SDF-1(G2) addition is not significant (P > .05).

Abbreviations are explained in Table 1.

We then asked whether the endogenously produced SDF-1 has a significant role in regulating the proliferative status of HPP-CFCs in these LTCs, as shown previously for TGF-β and MCP-1.11 15 LTCs were therefore set up as before with normal adult human marrow cells. At 2 to 3 days after the half-medium change on day 7, we added 30 μg/mL anti–SDF-1 antibody (or control immunoglobulin, at a similar final concentration) or 10 μg/mL SDF-1(G2), the SDF-1 antagonist. Then, another 4 to 5 days later, the numbers and cycling status of the CFCs in the adherent layer were assessed to determine whether these treatments would prevent the previously activated HPP-CFCs from reverting to a quiescent state. As anticipated from previous studies, no S-phase HPP-CFCs were detectable in the adherent layer of the control cultures (low percentage killed), although all of the LPP-CFCs present in the assays remained in cycle (high percentage killed; Table3). In contrast, a majority of the HPP-CFCs in the adherent layer of the cultures to which either SDF-1 blocking agent had been added were still in S-phase (high percentage killed; Table 3), without affecting their absolute numbers (data not shown). These results indicate that SDF-1 is another endogenously produced specific inhibitor of normal human HPP-CFC cycling that helps to regulate their rate of turnover in the LTC system.

Table 3.

Addition of an anti–SDF-1 antibody or SDF-1 antagonist to previously activated LTCs of normal bone marrow cells prevents the return of the primitive CFCs in the adherent layer to a quiescent state 4 to 5 days later

AdditionKilled by 3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 0 ± 4 4 ± 5 43 ± 2 
Anti–SDF-1 antibody 36 ± 3 44 ± 4 38 ± 3 
Control antibody 0 ± 8 12 ± 6 44 ± 2  
SDF-1 (G2) 49 ± 3 51 ± 5 38 ± 1 
AdditionKilled by 3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 0 ± 4 4 ± 5 43 ± 2 
Anti–SDF-1 antibody 36 ± 3 44 ± 4 38 ± 3 
Control antibody 0 ± 8 12 ± 6 44 ± 2  
SDF-1 (G2) 49 ± 3 51 ± 5 38 ± 1 

Anti-SDF-1 (and control antibody) were added at 30 μg/mL, and SDF-1(G2) was added at 10 μg/mL. Results shown are the mean ± SEM of data from 4 independent experiments. Both the anti–SDF-1 antibody and SDF-1(G2) had a significant effect compared with no addition (P < .001) or control antibody (P < .01) on the cycling of the primitive BFU-Es and primitive CFU-GMs, but not on the mature CFU-GMs (P > .05). The total colony counts in the control groups (no3H-thymidine) ranged from 14 to 134.

Insensitivity of CML HPP-CFCs to the cytostatic effect SDF-1 has on normal HPP-CFCs

In past experiments, we have shown that Ph+ HPP-CFCs are usually prevalent for the first 2 to 3 weeks in the adherent layer of LTCs initiated with peripheral blood cells from patients with CML with expanded clones of neoplastic cells (as indicated by the presence of a high WBC count). However, unlike their normal counterparts, these neoplastic HPP-CFCs remain continuously in cycle, even when the original irradiated adherent layer is derived from normal marrow.44 The anomalous proliferative activity of the CML HPP-CFCs in the LTC system can be attributed at least in part to their failure to respond to endogenously produced MCP-1 that inhibits normal HPP-CFC cycling in this system.15 CML HPP-CFCs also fail to respond to the cytostatic action that MIP-1α has on normal progenitors,16 suggesting a broader mechanism of BCR-ABL–mediated interference of signaling events activated by multiple chemokine receptors. Consistent with this hypothesis is the recently demonstrated inability of BCR-ABL–transduced murine BAF/3 cells to respond to SDF-1.45 We therefore predicted that the cycling of CML HPP-CFCs might also be unresponsive to SDF-1. To test this possibility, CML LTCs were initiated by placing cells from 7 patients with CML with high WBC counts onto pre-established irradiated normal marrow feeders. After 7 to 10 days, 100 ng/mL SDF-1 was added, and its effect on the cycling of the CML HPP-CFCs in the adherent layer was assessed another 2 to 3 days later. As a negative control, some cultures were left untouched. As a positive control, 5 ng/mL TGF-β was added to a third set of cultures. As expected, a high proportion of the HPP-CFCs harvested from the adherent layer of the control (untreated) CML LTCs were in S-phase (high percentage killed), and the proliferation of the neoplastic HPP-CFCs was completely, specifically, and reversibly arrested in parallel cultures to which 5 ng/mL TGF-β was added (low percentage of the HPP-CFCs killed, with persisting high percentages of the LPP-CFCs in the same cultures killed; Table4). The addition of SDF-1 had no effect on the cycling of any type of CML CFCs (Table 4), even when the concentration added was increased to 1 μg/mL (data not shown), a 10-fold higher concentration than that shown to be active on normal HPP-CFCs (Table 1). None of the treatments had any effect on absolute CFC numbers (data not shown).

Table 4.

Lack of effect of SDF-1 on the cycling of primitive progenitors in the adherent layer of CML LTCs assessed 2 to 3 days after a previous half-medium change

Factor addedKilled by 3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 56 ± 3 43 ± 3 39 ± 3 
SDF-1 55 ± 5 55 ± 5 41 ± 3 
TGF-β 0 ± 3 0 ± 6 34 ± 3 
Factor addedKilled by 3H-thymidine (%)
Primitive BFU-EsCFU-GMs
PrimitiveMature
None 56 ± 3 43 ± 3 39 ± 3 
SDF-1 55 ± 5 55 ± 5 41 ± 3 
TGF-β 0 ± 3 0 ± 6 34 ± 3 

SDF-1 was added at 100 ng/mL and TGF-β was added at 5 ng/mL. The results shown are the mean ± SEM of 7 independent experiments. SDF-1 had no significant effect on the cycling of any CML progenitor type whereas the effects of TGF-β on the cycling of the primitive BFU-Es and primitive CFU-GMs were significant (P < .001), although TGF-β did not significantly (P > .05) affect the cycling of the mature CFU-GMs. The total colony counts in the control groups (no3H-thymidine) ranged from 10 to 70.

SDF-1 inhibits the cycling of normal human LTC-ICs as well as HPP-CFCs in engrafted NOD/SCID mice

To investigate whether the effect of SDF-1 observed in vitro could be seen in vivo and to extend the evaluation to an even earlier progenitor cell type (LTC-ICs), we used the human NOD/SCID xenograft model. We also used a protocol that had previously allowed the differential in vivo inhibitory effects of MIP-1α, MCP-1, and TGF-β on human CFC and LTC-IC cycling to be demonstrated in this model.21 Accordingly, mice received transplants of 107 human cord blood cells to give reproducibly high levels of engraftment, and 6 to 8 weeks later they were injected on 2 consecutive days with SDF-1 (10 μg per injection per mouse). They were then killed 1 day later for analysis of any effects on human cell engraftment or progenitor cycling activity. The pooled results from 4 such experiments (2 to 4 mice per group per experiment) are shown in Figures 1 and2. The SDF-1 treatment had no significant immediate effects on any of the 5 parameters of human cell engraftment measured (P > .05). These consisted of the total number of human hematopoietic cells present in the marrow of the mice as well as the number of maturing human lymphoid and myeloid cells, the number of more primitive human CD34+cells, and the numbers of CFCs and LTC-ICs detected in the isolated human CD34+ population (Figure 1).

Fig. 1.

Lack of effect of SDF-1 administration on level of engraftment of NOD/SCID mice with human cells.

■, control mice injected with medium; ▪, SDF-1–treated mice. Values are the mean ± SEM of the total number of human cells of each type shown measured in 4 experiments. In each of these experiments, groups of 2 to 4 mice were injected with cord blood cells pooled from 1 to 3 donors and were then each injected 6 to 8 weeks later with 10 μg SDF-1 (or PBS) per mouse on 2 consecutive days prior to being killed and assessed on the third day. No significant difference (P > .05) was observed between the level of human cells in the control and SDF-1–treated animals for any of the human cell types examined.

Fig. 1.

Lack of effect of SDF-1 administration on level of engraftment of NOD/SCID mice with human cells.

■, control mice injected with medium; ▪, SDF-1–treated mice. Values are the mean ± SEM of the total number of human cells of each type shown measured in 4 experiments. In each of these experiments, groups of 2 to 4 mice were injected with cord blood cells pooled from 1 to 3 donors and were then each injected 6 to 8 weeks later with 10 μg SDF-1 (or PBS) per mouse on 2 consecutive days prior to being killed and assessed on the third day. No significant difference (P > .05) was observed between the level of human cells in the control and SDF-1–treated animals for any of the human cell types examined.

Close modal
Fig. 2.

Inhibitory effect of SDF-1 on the cycling activity of human HPP-CFCs and LTC-ICs in engrafted NOD/SCID mice.

Experiments are the same as those used to generate the data shown in Figure 1, but in this case, the values are the mean ± SEM of the percentage killed for each type of progenitor assessed after exposure of sorted human CD34+ cells to high–specific activity3H-thymidine either for 20 minutes (CFCs) or overnight (LTC-ICs). Data marked by asterisks indicate a significant difference from the corresponding control value (P < .001). The total colony counts in the control groups (no 3H-thymidine) ranged from 10 to 134.

Fig. 2.

Inhibitory effect of SDF-1 on the cycling activity of human HPP-CFCs and LTC-ICs in engrafted NOD/SCID mice.

Experiments are the same as those used to generate the data shown in Figure 1, but in this case, the values are the mean ± SEM of the percentage killed for each type of progenitor assessed after exposure of sorted human CD34+ cells to high–specific activity3H-thymidine either for 20 minutes (CFCs) or overnight (LTC-ICs). Data marked by asterisks indicate a significant difference from the corresponding control value (P < .001). The total colony counts in the control groups (no 3H-thymidine) ranged from 10 to 134.

Close modal

In contrast, as shown in Figure 2, selective and significant effects on the proliferative activity of different subsets of these human progenitors were observed when the sorted human CD34+ cells were first exposed to high–specific activity 3H-thymidine (for 20 minutes to assess the cycling activity of the CFCs and overnight for the LTC-ICs, as described in “Materials and methods”). In mice given SDF-1, the proportion of S-phase progenitors in all of the primitive progenitor compartments was markedly reduced (P < .001). This included both erythroid and granulopoietic HPP-CFCs subsets as well as the LTC-ICs. In contrast, administration of SDF-1 had no effect on the high cycling activity of the mature CFU-GMs (LPP-CFCs) present in the same mice, as shown by the persistence (P > .05) of a high fraction of S-phase LPP-CFCs (mature CFU-GMs) in the same assays.

Evidence that SDF-1 is an endogenous in vivo regulator of primitive human progenitor proliferation

We next asked whether SDF-1 produced endogenously in vivo might contribute to the downregulation of human CFC cycling. This occurs by 10 to 12 weeks after transplantation in NOD/SCID mice engrafted with normal human marrow cells (but not after the transplantation of cord blood cells20) and was previously shown to be mediated in part by MCP-1 and possibly MIP-1α with the use of in vivo treatments of such mice with antagonists of these chemokines.21 We therefore transplanted human marrow cells into mice and then injected each mouse with 2 daily doses of 10 μg SDF-1(G2), a specific antagonist of SDF-1,46 (or with PBS) 10 weeks later, by which time most of the human CFCs have become quiescent,19even though the human LTC-ICs in the same mice continue to proliferate.21 At 1 day later, the mice were killed, and any effects on human cell engraftment or progenitor cycling were determined. As illustrated in Figure 3, this protocol of SDF-1(G2) treatment had no significant effect on any of the 5 parameters of human cell engraftment assessed (P > .05). However, it did cause a specific reactivation of human HPP-CFC (but not LPP-CFC) cycling, as shown by the significantly increased (P < .001) sensitivity of the HPP-CFCs (but not the LPP-CFCs) to a 20-minute exposure to high–specific activity 3H-thymidine (Figure4). In the same mice, the turnover of the human LTC-ICs was already maximal in the absence of any treatment, as found previously,21 and administration of SDF-1(G2) did not change this.

Fig. 3.

Lack of effect of an SDF-1 antagonist on the level of human cell engraftment in NOD/SCID mice.

The number of different types of human cells present in the marrow of NOD/SCID mice was assessed 10 to 12 weeks after their transplantation with human marrow cells and 1 day after 2 daily injections of 10 μg SDF-1(G2) (▪) or PBS (■) per mouse. Values are the mean ± SEM of the total number of each human cell type determined in 6 experiments. In each of these experiments, groups of 2 to 4 mice were injected with cells from a different normal marrow sample. No significant difference (P > .05) between controls and SDF-1(G2)–treated animals was observed for any of the cell types examined.

Fig. 3.

Lack of effect of an SDF-1 antagonist on the level of human cell engraftment in NOD/SCID mice.

The number of different types of human cells present in the marrow of NOD/SCID mice was assessed 10 to 12 weeks after their transplantation with human marrow cells and 1 day after 2 daily injections of 10 μg SDF-1(G2) (▪) or PBS (■) per mouse. Values are the mean ± SEM of the total number of each human cell type determined in 6 experiments. In each of these experiments, groups of 2 to 4 mice were injected with cells from a different normal marrow sample. No significant difference (P > .05) between controls and SDF-1(G2)–treated animals was observed for any of the cell types examined.

Close modal
Fig. 4.

Effect of administration of an SDF-1 antagonist on the cycling of quiescent human HPP-CFCs in engrafted NOD/SCID mice.

Administration of an SDF-1 antagonist can reactivate the cycling of quiescent human HPP-CFCs in engrafted NOD/SCID mice. Data are from the same mice used for Figure 3, but in this case, the values are the mean ± SEM of the percentage killed as assessed after exposure of sorted human CD34+ cells to high–specific activity3H-thymidine for 20 minutes (or overnight for the LTC-ICs). Data marked by an asterisk indicate a significant difference from the control value (P < .001). The total colony counts in the control groups (no 3H-thymidine) ranged from 10 to 126.

Fig. 4.

Effect of administration of an SDF-1 antagonist on the cycling of quiescent human HPP-CFCs in engrafted NOD/SCID mice.

Administration of an SDF-1 antagonist can reactivate the cycling of quiescent human HPP-CFCs in engrafted NOD/SCID mice. Data are from the same mice used for Figure 3, but in this case, the values are the mean ± SEM of the percentage killed as assessed after exposure of sorted human CD34+ cells to high–specific activity3H-thymidine for 20 minutes (or overnight for the LTC-ICs). Data marked by an asterisk indicate a significant difference from the control value (P < .001). The total colony counts in the control groups (no 3H-thymidine) ranged from 10 to 126.

Close modal

The chemokines compose a large family of structurally related low-molecular-weight (6- to 14-kd) proteins that function as major regulators of leukocyte migration, activation, and chemotaxis during inflammatory processes.47 A number of chemokines have also been shown to have the ability to inhibit the proliferation of primitive hematopoietic cells.15,16,48 However, the latter effect appears to be quite dependent on the context in which the cells are exposed because the chemokines found to be active as inhibitors of primitive hematopoietic cells in the LTC system15 cover a much more selective spectrum than the chemokines reported to be active in dilute suspension cultures.48 The chemokines have been broadly classified into 4 subgroups on the basis of the position of the first 2 cysteines that form essential disulphide bonds. MIP-1α and MCP-1, the only 2 chemokines previously shown to be inhibitors of normal human HPP-CFC cycling either in the LTC system or in xenografted NOD/SCID mice,21 are both classified as CC chemokines because the first 2 cysteines are adjacent. HCC-1 and I-309, also tested here, are both members of the CC family. On the other hand, SDF-1 is a member of the CXC subset in which these cysteines are separated by another amino acid.

The chemokine receptors belong to the heptahelical receptor superfamily, which, upon ligand binding, couple trimeric guanine-nucleotide binding (G) proteins and activate calcium flux changes. Because the ligand-binding abilities of many chemokine receptors overlap extensively and many individual cell types express a number of different chemokine receptors, the mechanisms by which specific chemokine effects are mediated have often been difficult to elucidate. For example, MIP-1α−/− mice do not show any obvious perturbation of hematopoiesis or other defects in their normal physiology except for a compromised ability to respond to viral infections.49 MCP-1−/− mice have also not been reported to display any alteration in blood cell production50 consistent with the observed overlap in the hematopoietic regulatory activities of these cytokines in vitro. However, although CC receptor 2−/− mice develop normally, a significant defect in monocyte/macrophage recruitment and in interferon-γ production has been seen.51 

SDF-1 is different from many of the other chemokines in its apparent specificity for a single receptor, CXCR4 (previously referred to as LESTR, HUMSTER, or fusin),52-54 and its much broader range of action. CXCR4 is expressed on lymphocytes and monocytes,38,55 megakaryocytes,56 and dendritic cells, as well as primitive progenitors in the hematopoietic system, including CFCs and LTC-ICs.22-24,28,57 CXCR4 is also expressed on cells in a wide variety of other organs and tissues, including heart, brain, spleen, liver, and colon.52,53,58-61 SDF-1 is produced constitutively in many tissues, including bone marrow, thymus, spleen, heart, lung, muscle, kidney, and liver.40,62,63 This contrasts with many other chemokines whose expression is highly regulated by proinflammatory cytokines and has led to the idea that SDF-1 plays a role in steady-state homeostatic processes, including leukocyte and hematopoietic stem cell trafficking24-29,38; B lymphopoiesis; establishment of marrow myelopoiesis during embryogenesis; neurogenesis; cardiogenesis; and blood vessel formation.23,60-62,64 65 

In this paper, we provide evidence for the first time of a chemokine, SDF-1, that can function as an inhibitor of human LTC-IC cycling. In addition, SDF-1 inhibited the cycling activity of HPP-CFCs, but not the more mature LPP-CFCs, both in vivo and in vitro (in the adherent layer of LTCs). The latter mimic the effects we have previously documented for TGF-β, MCP-1, and MIP-1α tested in the same type of experiment.12,15,16 Interestingly, however, studies in the NOD/SCID model have shown that each of these cytokines regulates the proliferation of a slightly different range of human progenitor types, with only TGF-β and SDF-1 being active on human LTC-ICs.21 These findings support, although they do not prove, a direct action of each of these cytokines on the various subsets of human progenitors affected. The broader range of SDF-1 activity may be explained simply by a potentially broader range of CXCR4 expression on human CD34+ cells. Future studies of chemokine receptor expression on functionally tested purified subpopulations of CD34+ cells should help to address this possibility.

The effect of SDF-1 on the proliferation of hematopoietic cells in other studies appears to be contradictory. In some studies, no effect on progenitor cycling was discerned.25,56,66 On certain myeloid progenitor cell lines, a suppressive effect of SDF-1 was reported,67 although this was not the case for others, in spite of expression of functional CXCR4.68 In combination with other cytokines, SDF-1 was actually found to promote the proliferation of human CD34+ cells purified from normal adult peripheral blood although when SDF-1 was added alone, only survival was supported, not mitogenesis.69 These findings highlight the role other factors can have in influencing the effects chemokines exert on hematopoietic cell proliferation control as well as the importance of the progenitor subset investigated, as is also indicated by earlier evidence of opposing actions of MIP-1α (and TGF-β) in stimulating the proliferation of later progenitor types but inhibiting their more primitive precursors.70-72 

The present findings also show that endogenously produced SDF-1 can, like endogenously produced MIP-1α and/or MCP-1, contribute to the negative regulation of primitive adult human marrow–derived CFCs being regenerated in a foreign environment. Nevertheless, evidence of endogenous chemokine-mediated inhibition of proliferation of the human LTC-ICs present in the same mice was not seen although such a response could be elicited when a large dose of exogenous SDF-1 was injected. Given the differences in types and concentrations of other cytokines already known to characterize the responses of hematopoietic progenitors at different stages of differentiation, a differential effect of endogenous SDF-1 on human HPP-CFCs and LTC-ICs in engrafted NOD/SCID mice may be explained in a similar way. It would also be interesting to determine whether the late-onset chemokine-mediated inhibition of human CFC proliferation seen in human marrow–engrafted NOD/SCID mice (and/or the corresponding lack of inhibition of human LTC-IC proliferation) is unique to this model, or whether these are also features of syngeneic or allogeneic transplants.

Several groups have demonstrated the ability of marrow-derived stromal feeder layers and cell lines to inhibit the proliferation of primitive hematopoietic progenitors. In addition, LTC-IC and CFC production has been shown to be increased when direct contact with the stromal layer is prevented,73 and evidence of a role of integrin receptors in the adhesion required to downregulate progenitor cycling has been reported.74 Similarly, it has been suggested that the abnormal proliferative activity of CML progenitors within the adherent layer of the LTC system is caused at least in part by the abnormal adhesive properties of CML progenitors.75-77However, we have shown that primitive CML cells can be stimulated to proliferate autonomously by an autocrine IL-3/G-CSF–mediated mechanism.78 This could also explain the generic ability of primitive CML cells to overcome a common mechanism of chemokine-activated cycling inhibition that may be operative in normal progenitors and that may include potential secondary effects on integrin activation.

Finally, our findings suggest that SDF-1, because of its activity on very primitive hematopoietic cells, may (unlike MIP-1α or MCP-1) have potential therapeutic value as a stem cell protective agent in patients undergoing extensive chemotherapy. Such treatments are generally believed to activate and hence sensitize the stem cell compartment so that the stem cells' acquired sensitivity to later cycles of drugs that target dividing cells becomes dose limiting. The use of SDF-1 in such circumstances could be of particular benefit to patients whose malignant progenitors are unresponsive to SDF-1, as suggested here for CML.

We thank members of the Stem Cell Assay Service for assistance in the initial processing of cord blood, bone marrow, and CML blood cells, and members of the Flow Cytometry Service for assistance in the FACS isolation of human CD34+ cells. We also thank P. Lansdorp, StemCell Technologies, Cangene, Chemokine Therapeutics, and Novartis for generous gifts of reagents, and A. Ahamed for assistance in preparing the manuscript.

Supported by grants from the National Cancer Institute of Canada, with funds from the Canadian Cancer Society and the Terry Fox Run and PO1 55435 (National Heart, Lung, and Blood Institute), and by Canadian Institutes of Health Research grant 36346.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Becker
AJ
McCulloch
EA
Siminovitch
L
Till
JE
The effect of differing demands for blood cell production on DNA synthesis by hemopoietic colony-forming cells of mice.
Blood.
26
1965
296
308
2
Hodgson
GS
Bradley
TR
In vivo kinetic states of hematopoietic stem and progenitor cells as inferred from labelling with bromodeoxyuridine.
Exp Hematol.
12
1984
683
687
3
Bradford
GB
Williams
B
Rossi
R
Bertoncello
I
Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment.
Exp Hematol.
25
1997
445
453
4
Eaves
CJ
Eaves
AC
Cell culture studies in CML.
Bailliere's Clinical Haematology. London
Hinton
K
1987
931
961
Bailliere Tindall/WB Saunders
United Kingdom
5
Ponchio
L
Conneally
E
Eaves
C
Quantitation of the quiescent fraction of long-term culture-initiating cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro.
Blood.
86
1995
3314
3321
6
Reems
JA
Torok-Storb
B
Cell cycle and functional differences between CD34+/CD38hi and CD34+/38lo human marrow cells after in vitro cytokine exposure.
Blood.
85
1995
1480
1487
7
Jordan
CT
Yamasaki
G
Minamoto
D
High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations.
Exp Hematol.
24
1996
1347
1355
8
Fleming
WH
Alpern
EJ
Uchida
N
Ikuta
K
Spangrude
GJ
Weissman
IL
Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells.
J Cell Biol.
122
1993
897
902
9
Rufer
N
Brummendorf
TH
Kolvraa
S
et al
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood.
J Exp Med.
190
1999
157
167
10
Cashman
J
Eaves
AC
Eaves
CJ
Regulated proliferation of primitive hematopoietic progenitor cells in long-term human marrow cultures.
Blood.
66
1985
1002
1005
11
Eaves
CJ
Cashman
JD
Kay
RJ
et al
Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures, II: analysis of positive and negative regulators produced by stromal cells within the adherent layer.
Blood.
78
1991
110
117
12
Cashman
JD
Eaves
AC
Raines
EW
Ross
R
Eaves
CJ
Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures, I: stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β.
Blood.
75
1990
96
101
13
Hogge
DE
Cashman
JD
Humphries
RK
Eaves
CJ
Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures.
Blood.
77
1991
493
499
14
Otsuka
T
Thacker
JD
Hogge
DE
The effects of interleukin 6 and interleukin 3 on early hematopoietic events in long-term cultures of human marrow.
Exp Hematol.
19
1991
1042
1048
15
Cashman
JD
Eaves
CJ
Sarris
AH
Eaves
AC
MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures.
Blood.
92
1998
2338
2344
16
Eaves
CJ
Cashman
JD
Wolpe
SD
Eaves
AC
Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1α, an inhibitor of primitive normal hematopoietic cells.
Proc Natl Acad Sci U S A.
90
1993
12015
12019
17
Maguer-Satta
V
Burl
S
Liu
L
et al
BCR-ABL accelerates C2-ceramide-induced apoptosis.
Oncogene.
16
1998
237
248
18
Cashman
JD
Eaves
AC
Eaves
CJ
Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-β on normal and leukemic human hematopoietic progenitor cells.
Leukemia.
6
1992
886
892
19
Cashman
JD
Lapidot
T
Wang
JCY
et al
Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice.
Blood.
89
1997
4307
4316
20
Cashman
J
Bockhold
K
Hogge
DE
Eaves
AC
Eaves
CJ
Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haematopoietic cells in NOD/SCID mice transplanted with human cord blood.
Br J Haematol.
97
1997
1026
1036
21
Cashman
JD
Clark-Lewis
I
Eaves
AC
Eaves
CJ
Differentiation stage-specific regulation of primitive human hematopoietic progenitor cycling by exogenous and endogenous inhibitors in an in vivo model.
Blood.
94
1999
3722
3729
22
Mohle
R
Bautz
F
Rafii
S
Moore
MAS
Brugger
W
Kanz
L
The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.
Blood.
91
1998
4523
4530
23
Aiuti
A
Tavian
M
Cipponi
A
et al
Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors.
Eur J Immunol.
29
1999
1823
1831
24
Jo
D-Y
Rafii
S
Hamada
T
Moore
MAS
Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1.
J Clin Invest.
105
2000
101
111
25
Auiti
A
Webb
IJ
Bleul
C
Springer
T
Gutierrez-Ramos
JC
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.
J Exp Med.
185
1997
111
120
26
Naiyer
AJ
Jo
D-Y
Ahn
J
et al
Stromal derived factor-1-induced chemokinesis of cord blood CD34+ cells (long-term culture-initiating cells) through endothelial cells is mediated by E-selectin.
Blood.
94
1999
4011
4019
27
Peled
A
Petit
I
Kollet
O
et al
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.
Science.
283
1999
845
848
28
Shen
H
Cheng
T
Olszak
I
et al
CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells.
J Immunol.
166
2001
5027
5033
29
Hattori
K
Heissig
B
Tashiro
K
et al
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells.
Blood.
97
2001
3354
3360
30
Schulz-Knappe
P
Magert
H-J
Dewald
B
et al
HCC-1, a novel chemokine from human plasma.
J Exp Med.
183
1996
295
299
31
Miller
MD
Hata
S
de Waal Malefyt
R
Krangel
MS
A novel polypeptide secreted by activated human T lymphocytes.
J Immunol.
1
1989
2907
2916
32
Crump
MP
Gong
J-H
Loetscher
P
et al
Solution structure and basis for functional activity of stromal cell-derived factor-1: dissociation of CXCR4 activation from binding and inhibition of HIV-1.
EMBO J.
16
1997
6996
7007
33
Gong
J-H
Clark-Lewis
I
Antagonists of monocyte chemoattractant protein-1 identified by modification of functionally critical NH2-terminal residues.
J Exp Med.
181
1995
631
640
34
Thomas
TE
Miller
CL
Eaves
CJ
Purification of hematopoietic stem cells for further biological study.
Methods.
17
1999
202
218
35
Unkeless
JC
Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.
J Exp Med.
150
1979
580
596
36
Schmitt
C
Eaves
CJ
Lansdorp
PM
Expression of CD34 on human B cell precursors.
Clin Exp Immunol.
85
1991
168
173
37
Hogge
DE
Lansdorp
PM
Reid
D
Gerhard
B
Eaves
CJ
Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor.
Blood.
88
1996
3765
3773
38
Bleul
CC
Fuhlbrigge
RC
Casasnovas
JM
Aiuti
A
Springer
TA
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1).
J Exp Med.
184
1996
1101
1109
39
Iami
K
Kobayashi
M
Wang
J
et al
Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow.
Br J Haematol.
106
1999
905
911
40
Nagasawa
T
Kikutani
H
Kishimoto
T
Molecular cloning and structure of a pre-B-cell growth-stimulating factor.
Proc Natl Acad Sci U S A.
91
1994
2305
2309
41
Simmons
PJ
Przepiorka
D
Thomas
ED
Torok-Storb
B
Host origin of marrow stromal cells following allogeneic bone marrow transplantation.
Nature.
328
1987
429
432
42
Andreoni
C
Moreau
I
Rigal
D
Long-term culture of human bone marrow, I: characterization of adherent cells in flow cytometry.
Exp Hematol.
18
1990
431
437
43
Otsuka
T
Thacker
JD
Eaves
CJ
Hogge
DE
Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells.
J Clin Invest.
88
1991
417
422
44
Eaves
AC
Cashman
JD
Gaboury
LA
Kalousek
DK
Eaves
CJ
Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells.
Proc Natl Acad Sci U S A.
83
1986
5306
5310
45
Salgia
R
Quackenbush
E
Lin
J
et al
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1α.
Blood.
94
1999
4233
4246
46
Loetscher
P
Gong
J-H
Dewald
B
Baggiolini
M
Clark-Lewis
I
N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities.
J Biol Chem.
273
1998
22279
22283
47
Rollins
BJ
Chemokines.
Blood.
90
1997
909
928
48
Broxmeyer
HE
Sherry
B
Cooper
S
et al
Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells.
J Immunol.
150
1993
3448
3458
49
Cook
DN
Beck
MA
Coffman
TM
et al
Requirement of MIP-1α for an inflammatory response to viral infection.
Science.
269
1995
1583
1585
50
Lu
B
Rutledge
BJ
Gu
L
et al
Abnormalities in monocyte recuitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice.
J Exp Med.
187
1998
601
608
51
Boring
L
Gosling
J
Chensue
SW
et al
Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice.
J Clin Invest.
100
1997
2552
2561
52
Federsppiel
B
Melhado
IG
Duncan
AMV
et al
Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen.
Genomics.
16
1993
707
712
53
Loetscher
M
Geiser
T
O'Reilly
T
Zwahlen
R
Baggiolini
M
Moser
B
Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.
J Biol Chem.
269
1994
232
237
54
Feng
Y
Broder
CC
Kennedy
PE
Berger
EA
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science.
272
1996
872
877
55
Förster
A
Kremmer
E
Schubel
A
et al
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation.
J Immunol.
160
1998
1522
1531
56
Wang
J-F
Liu
Z-Y
Groopman
JE
The α-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion.
Blood.
92
1998
756
764
57
Rosu-Myles
M
Gallacher
L
Murdoch
B
et al
The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression.
Proc Natl Acad Sci U S A.
97
2000
14626
14631
58
Tanabe
S
Heesen
M
Yoshizawa
I
et al
Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes.
J Immunol.
159
1997
905
911
59
Volin
MV
Joseph
L
Shockley
MS
Davies
PF
Chemokine receptor CXCR4 expression in endothelium.
Biochem Biophys Res Commun.
242
1998
46
53
60
Zou
Y-R
Kottmann
AH
Kuroda
M
Taniuchi
I
Littman
DR
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.
Nature.
393
1998
595
599
61
Tachibana
K
Hirota
S
Iizasa
H
et al
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature.
393
1998
591
594
62
McGrath
KE
Koniski
AD
Maltby
KM
McGann
JK
Palis
J
Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4.
Dev Biol.
213
1999
442
456
63
Tashiro
K
Tada
H
Heilker
R
Shirozu
M
Nakano
T
Honjo
T
Signal sequence trap: a cloning strategy for secreted proteins and type l membrane proteins.
Science.
261
1993
600
603
64
Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;635-638.
65
Ma
Q
Jones
D
Borghesani
PR
et al
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1 deficient mice.
Proc Natl Acad Sci U S A.
95
1998
9448
9453
66
Broxmeyer
HE
Kim
CH
Cooper
SH
Hangoc
G
Hromas
R
Pelus
LM
Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors.
Ann N Y Acad Sci.
872
1999
142
162
67
Sanchez
X
Cousins-Hodges
B
Aguilar
T
Gosselink
P
Lu
Z
Navarro
J
Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression.
J Biol Chem.
272
1997
27529
27531
68
Majka
M
Rozmyslowicz
T
Honczarenko
M
et al
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia.
14
2000
1821
1832
69
Lataillade
J-J
Clay
D
Dupuy
C
et al
Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival.
Blood.
95
2000
756
768
70
Keller
JR
Jacobsen
SEW
Dubois
CM
Hestdal
K
Ruscetti
FW
Transforming growth factor-β: a bidirectional regulator of hematopoietic cell growth.
Int J Cell Cloning.
10
1992
2
11
71
Broxmeyer
HE
Sherry
B
Lu
L
et al
Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells.
Blood.
76
1990
1110
1116
72
Van Ranst
PCF
Snoeck
H-W
Lardon
F
et al
TGF-β and MIP-1α exert their main inhibitory activity on very primitive CD34++CD38− cells but show opposite effects on more mature CD34+CD38+ human hematopoietic progenitors.
Exp Hematol.
24
1996
1509
1515
73
Verfaillie
CM
Catanzaro
P
Direct contact with stroma inhibits proliferation of human long-term culture initiating cells.
Leukemia.
10
1996
498
504
74
Hurley
RW
McCarthy
JB
Verfaillie
CM
Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation.
J Clin Invest.
96
1995
511519
75
Gordon
MY
Dowding
CR
Riley
GP
Goldman
JM
Greaves
MF
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia.
Nature.
328
1987
342
344
76
Verfaillie
CM
McCarthy
JB
McGlave
PB
Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia.
J Clin Invest.
90
1992
1232
1241
77
Bhatia
R
McGlave
PB
Verfaillie
CM
Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors.
J Clin Invest.
96
1995
931
939
78
Jiang
X
Lopez
A
Holyoake
T
Eaves
A
Eaves
C
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.
Proc Natl Acad Sci U S A.
96
1999
12804
12809

Author notes

C. J. Eaves, Terry Fox Laboratory, 601 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada; e-mail:ceaves@bccancer.bc.ca.

Sign in via your Institution